

Rodrigo Liberal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8390014/publications.pdf>

Version: 2024-02-01

57
papers

2,483
citations

236612

25
h-index

197535

49
g-index

58
all docs

58
docs citations

58
times ranked

2937
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulatory T-cells in autoimmune diseases: Challenges, controversies and “yet” unanswered questions. <i>Autoimmunity Reviews</i> , 2015, 14, 105-116.	2.5	226
2	Autoimmune hepatitis: A comprehensive review. <i>Journal of Autoimmunity</i> , 2013, 41, 126-139.	3.0	176
3	Dysfunctional CD39 ^{POS} regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis. <i>Hepatology</i> , 2014, 59, 1007-1015.	3.6	158
4	Review article: COVID-19 and liver disease “what we know on 1st May 2020. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 267-275.	1.9	137
5	Pathogenesis of autoimmune hepatitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 653-664.	1.0	131
6	The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway. <i>Hepatology</i> , 2012, 56, 677-686.	3.6	126
7	Diagnostic criteria of autoimmune hepatitis. <i>Autoimmunity Reviews</i> , 2014, 13, 435-440.	2.5	101
8	Inhibition of Interleukin-17 Promotes Differentiation of CD25 Cells Into Stable T Regulatory Cells in Patients With Autoimmune Hepatitis. <i>Gastroenterology</i> , 2012, 142, 1526-1535.e6.	0.6	98
9	Autoimmune hepatitis: Contrasts and comparisons in children and adults “ A comprehensive review. <i>Journal of Autoimmunity</i> , 2013, 46, 7-16.	3.0	98
10	Cutting edge issues in autoimmune hepatitis. <i>Journal of Autoimmunity</i> , 2016, 75, 6-19.	3.0	96
11	Clinical significance of autoantibodies in autoimmune hepatitis. <i>Journal of Autoimmunity</i> , 2013, 46, 17-24.	3.0	85
12	Autoimmune Hepatitis After Liver Transplantation. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 346-353.	2.4	83
13	Liver transplantation and autoimmune liver diseases. <i>Liver Transplantation</i> , 2013, 19, 1065-1077.	1.3	83
14	In autoimmune hepatitis type 1 or the autoimmune hepatitis “sclerosing cholangitis variant defective regulatory T cell responsiveness to IL-2 results in low IL-10 production and impaired suppression. <i>Hepatology</i> , 2015, 62, 863-875.	3.6	83
15	Update on Autoimmune Hepatitis. <i>Journal of Clinical and Translational Hepatology</i> , 2015, 3, 42-52.	0.7	73
16	Autoimmune hepatitis after COVID-19 vaccine “ more than a coincidence. <i>Journal of Autoimmunity</i> , 2021, 125, 102741.	3.0	71
17	Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation?. <i>Liver Transplantation</i> , 2019, 25, 946-959.	1.3	59
18	Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 572-585.	0.7	54

#	ARTICLE	IF	CITATIONS
19	Possible involvement of CCL1-CCR8 interaction in lymphocytic recruitment in IgG4-related sclerosing cholangitis. <i>Journal of Hepatology</i> , 2013, 59, 1059-1064.	1.8	49
20	Cirrhosis and autoimmune liver disease: Current understanding. <i>World Journal of Hepatology</i> , 2016, 8, 1157.	0.8	47
21	CD39 mediated regulation of Th17-cell effector function is impaired in juvenile autoimmune liver disease. <i>Journal of Autoimmunity</i> , 2016, 72, 102-112.	3.0	40
22	Looking into Enteric Virome in Patients with IBD. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1278-1284.	0.9	39
23	Regulatory T cell conditioning endows activated effector T cells with suppressor function in autoimmune hepatitis/autoimmune sclerosing cholangitis. <i>Hepatology</i> , 2017, 66, 1570-1584.	3.6	39
24	Association Between Black Race and Presentation and Liver-Related Outcomes of Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1616-1624.e2.	2.4	31
25	Retinoic acid stabilizes antigen-specific regulatory T-cell function in autoimmune hepatitis type 2. <i>Journal of Autoimmunity</i> , 2014, 53, 26-32.	3.0	28
26	Porto-pulmonary hypertension: A comprehensive review. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 157-167.	0.7	26
27	Liver immunology: How to reconcile tolerance with autoimmunity. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 6-16.	0.7	24
28	The risk of liver cancer in autoimmune liver diseases. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986191.	1.4	23
29	Predictive models of mortality and hospital readmission of patients with decompensated liver cirrhosis. <i>Digestive and Liver Disease</i> , 2019, 51, 1423-1429.	0.4	23
30	Aberrant hepatic trafficking of gut-derived T cells is not specific to primary sclerosing cholangitis. <i>Hepatology</i> , 2022, 75, 518-530.	3.6	21
31	Primary biliary cholangitis in patients with inflammatory bowel disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, e5-e9.	0.7	18
32	Established and novel therapeutic options for autoimmune hepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 315-326.	3.7	17
33	Recurrence of autoimmune liver disease and inflammatory bowel disease after pediatric liver transplantation. <i>Liver Transplantation</i> , 2016, 22, 1275-1283.	1.3	15
34	Octreotide Long-Acting Release is effective in preventing gastrointestinal bleeding due to angiodysplasias. <i>GE Portuguese Journal of Gastroenterology</i> , 2014, 21, 176-183.	0.3	11
35	Management of autoimmune hepatitis: Focus on pharmacologic treatments beyond corticosteroids. <i>World Journal of Hepatology</i> , 2014, 6, 410.	0.8	11
36	Diego and Giorgina Vergani: The two hearts of translational autoimmunity. <i>Journal of Autoimmunity</i> , 2016, 66, 1-6.	3.0	10

#	ARTICLE	IF	CITATIONS
37	Effect of ethnicity on the clinical presentation and outcome of autoimmune hepatitis. Expert Review of Gastroenterology and Hepatology, 2012, 6, 267-269.	1.4	8
38	Hepatic granulomas: a 17-year single tertiary centre experience. Histopathology, 2018, 73, 240-246.	1.6	7
39	Endoscopic ultrasound in pancreatic cancer treatment: Facts and hopes. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 513-521.	0.7	6
40	Cirrhosis management in a major referral center during COVID-19. JHEP Reports, 2020, 2, 100146.	2.6	5
41	Long-term outcome of patients with difficult-to-treat autoimmune hepatitis receiving mycophenolate mofetil. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101487.	0.7	5
42	Discontinuation of antiviral therapy in chronic hepatitis B patients. World Journal of Clinical Cases, 2021, 9, 6979-6986.	0.3	4
43	Transient splenic elastography predicts high-risk esophageal varices in patients with non-cirrhotic portal hypertension. Scandinavian Journal of Gastroenterology, 2021, 56, 1462-1466.	0.6	4
44	HIPPOCRATES® project: A proof of concept of a collaborative program for hepatitis C virus micro-elimination in a prison setting. World Journal of Hepatology, 2020, 12, 1314-1325.	0.8	4
45	Contemporary issues and future directions in autoimmune hepatitis. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1163-1174.	1.4	3
46	Pediatric-onset primary biliary cholangitis. Digestive and Liver Disease, 2019, 51, 1064-1065.	0.4	3
47	Acute severe autoimmune hepatitis – timing for steroids and role of other immunosuppressive agents. Journal of Hepatology, 2021, 75, 494-495.	1.8	3
48	Clinical utility of the patency capsule: a large volume center experience. Minerva Gastroenterology, 2017, 64, 10-13.	0.3	3
49	Quality and competence in endoscopic retrograde cholangiopancreatography – Where are we 50 years later?. Digestive and Liver Disease, 2018, 50, 750-756.	0.4	1
50	Another clinical unmet need in liver patients: Multidrug resistant bacteria in decompensated cirrhosis. Journal of Hepatology, 2019, 71, 844-845.	1.8	1
51	Choosing an equation for glomerular filtration rate in decompensated cirrhosis: –Royal Free Hospital– formula is able to predict short-term mortality. International Urology and Nephrology, 2019, 51, 1279-1280.	0.6	1
52	Treatment response in primary biliary cholangitis: The role of autoimmune hepatitis features. Annals of Hepatology, 2019, 18, 488-493.	0.6	1
53	Mucosal Healing in Ulcerative Colitis Patients Treated With Vedolizumab: Patient-, Dose-, or Duration-Dependent?. Journal of Crohn's and Colitis, 2017, 11, 1403-1404.	0.6	0
54	Diagnostic performance and factors influencing the accuracy of EUS-FNA for pancreatic adenocarcinoma. Pancreatology, 2017, 17, S81-S82.	0.5	0

#	ARTICLE	IF	CITATIONS
55	Letter: liver disease and COVID-19 not the perfect storm. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 574-575.	1.9	0
56	Screening endoscopy in patients with cirrhosis: screening of varices and gastrointestinal neoplasia. Endoscopy, 2020, 52, 623-623.	1.0	0
57	Letter: unknown denominator and misleading conclusions in Covid-19 authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 1243-1244.	1.9	0